Dawn Bir is an accomplished executive with extensive experience in the biopharmaceutical industry, currently serving as a Member of the Board of Directors at Soleno Therapeutics, Inc. and Geron Corporation. Previously, Dawn held the position of Executive Vice President at Reata Pharmaceuticals, contributing to the company's growth and a significant acquisition by Biogen. Dawn's career includes key leadership roles such as Vice President of Commercial at Pharmacyclics, Vice President at McKesson, and various positions at Genentech and Bristol-Myers Squibb, showcasing a strong track record in sales, operations, and team development across multiple therapeutic areas. Dawn holds a Bachelor of Science degree in Biological Sciences from Binghamton University and is furthering education at Columbia Business School.
This person is not in the org chart
This person is not in any offices
Geron
4 followers
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.